Core Viewpoint - Clearmind Medicine Inc. has received Institutional Review Board (IRB) approval for its Phase 1/2a clinical trial of CMND-100, a MEAI-based oral drug candidate aimed at treating Alcohol Use Disorder (AUD) [1][3][4] Group 1: Clinical Trial Details - The trial will take place at Tel Aviv Sourasky Medical Center (TASMC) and includes participation from other prestigious institutions such as Yale School of Medicine and Johns Hopkins University [2] - The trial aims to assess the safety, tolerability, and pharmacokinetic profile of CMND-100, while also evaluating its preliminary efficacy in reducing alcohol cravings and consumption in patients with AUD [4] Group 2: Company Background and Objectives - Clearmind is focused on the discovery and development of novel psychedelic-derived therapeutics to address under-treated health issues, including AUD [5] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as necessary [6] Group 3: Market Context and Impact - AUD is a significant global health issue, accounting for 4.7% of all deaths worldwide, highlighting the urgent need for effective treatments [4] - The company aims to provide a transformative treatment for individuals affected by AUD, which impacts millions of lives globally [4]

What's being priced in. I mean, essentially, any time we get clarity, people say, oh, that's priced in. But the clarity is different every single day, whether it's the clarity of what kind of rate we're talking about with tariffs or the clarity of how big the US deficit is going to be, All of these worries that we had earlier in the year that are now being shrugged off as priced in, how do you determine between rational versus numb.I think it is entirely rational because when we look, for example, at what i ...

1. Report Industry Investment Rating No information about the industry investment rating is provided in the report. 2. Core Viewpoints of the Report - In H1 2025, convertible bonds showed an "N"-shaped upward fluctuation driven by multiple factors. The convertible bond index outperformed major stock indices, and the valuation increased by 3.58pct compared to the end of 2024. The convertible bond market experienced two rises and two falls, which can be divided into three stages: the valuation increase supported by the capital of convertible bonds from the end of 2024 to before the Spring Festival, the technology sector theme fever from after the Spring Festival to the end of March, and the callback and rebound of convertible bonds following the equity market under the tariff disturbances from early April to June [2][9]. - The convertible bond market presented strong performance. From the beginning of 2025 to June 30, the CSI Convertible Bond Index outperformed major equity market indices. The net value of convertible bond funds rose by 7.48% in H1 2025, better than that of first - and second - tier bond funds and partial - debt funds. The maximum drawdown of convertible bond funds was - 8.38%, which was better than that of stock - type and partial - stock - type funds [12]. 3. Summary According to Relevant Catalogs 3.1 2025H1 Convertible Bond Market: Fluctuating with the Underlying Stocks under the Macroeconomic Narrative, with Better Stability - **Convertible Bond Terms**: In 2025, the number of forced redemptions remained high. A total of 96 convertible bonds triggered the forced redemption clause, and 36 were announced for redemption, with a forced redemption probability of 37.5%, slightly lower than 42.4% in 2024. The number of times the downward revision clause was triggered decreased, and the probability of downward revision also declined. The number and balance of convertible bonds entering the put - back period were still large, but put - back events only occurred sporadically [3][21][22]. - **Supply - Demand Structure**: The supply improved significantly year - on - year but was uneven. A total of 19 convertible bonds were issued in H1 2025, with a scale of 21.775 billion yuan, up 58.33% and 68.66% respectively compared to H1 2024. High - rating and large - cap convertible bonds had relatively weak issuance. On the demand side, most major holders reduced their positions, but securities firms and private funds increased their holdings [4][30][42]. 3.2 Stage Review: Convertible Bonds' Resistance to Decline - Theme Fever - External Disturbances - **January 2 - January 27**: Equity market had a small "V" - shaped reversal, and convertible bonds maintained a high - level valuation. At the beginning of the year, the equity market's callback and the spill - over effect from pure bonds catalyzed a rapid increase in the valuation of convertible bonds. Insurance funds and ETFs' increased holdings supported the valuation. The 100 - yuan premium rate increased by 3.43pct to 24.10% [5][58][63]. - **February 5 - March 31**: The technology theme fever catalyzed the convertible bond market. After the Spring Festival, the technology theme drove the equity market, and the convertible bond market was affected by the redemption pressure of bond funds, with its elasticity being less than that of the equity market, and the valuation decreased by 1.82pct to 22.28% [5][58][66]. - **April 1 - June 30**: External uncertainties were controllable, and the hot spots shifted to the pharmaceutical and consumer sectors. The tariff disturbances led to a callback in the equity market in April, but the impact was controllable. The convertible bond style turned to be more stable, and the valuation was relatively firm. The 100 - yuan premium rate increased by 2.44pct to 24.72% [5][58][71].

Travel Tips - The document provides 10 essential travel tips for first-time visitors to Japan [1]

Core Viewpoint - The Chinese government is implementing a series of proactive macroeconomic policies to stabilize the market and expectations, with a focus on introducing new policy financial tools to address structural issues in various sectors [1][2]. Group 1: Financial Policy Measures - Since the Central Political Bureau meeting on April 25, a package of financial policies has been rapidly released to support market stability and expectations, including interest rate cuts and new structural monetary policy tools [1][2]. - The effectiveness of these policies is being observed, but experts suggest that new policy financial tools are still necessary to address ongoing structural contradictions in certain areas [1][2]. Group 2: New Policy Financial Tools - The new policy financial tools are expected to provide targeted support for key areas such as foreign trade, technological innovation, and consumption [2][3]. - In 2022, three policy financial institutions created and deployed approximately 740 billion yuan in policy and developmental financial tools, leading to a total credit limit of over 3.5 trillion yuan for supported projects [1]. Group 3: Support for Foreign Trade and Investment - Experts anticipate that new policy financial tools may include mechanisms similar to export buyer credit to support foreign trade enterprises and mitigate external demand fluctuations [3]. - The National Development and Reform Commission has indicated that these new tools will address capital shortages for project construction, potentially reviving and optimizing existing policy financial tools [3]. Group 4: Role of PSL and Fiscal Support - The People's Bank of China (PBOC) is expected to restart and expand the Pledged Supplementary Lending (PSL) program to provide long-term low-cost funding to policy banks [4][5]. - Fiscal support, such as interest subsidies, is deemed crucial for the effectiveness of new policy financial tools, as seen in previous initiatives where the central government provided significant interest subsidies to reduce project funding costs [4][5].

LGBTQ+ Rights & Legal Framework - Hong Kong proposes a legal recognition framework for same-sex partnerships [1] - This marks a significant advancement for the LGBTQ+ community in Hong Kong [1]

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive focuses on sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

What did you get done this quarter?For Pudgy Penguins, the list includes:- Getting CBOE to file for a PENGU + Pudgy ETF- Ringing the bell at Nasdaq- Partnerships with Nascar and Lufthansa- First Pudgy children's book with Randomhouse- Launch of Pengu Clash- PENGU on Upbit and Revolut- Pudgy Pez dispensers- Reaching 800M+ views per day+ a lot moreThis is the Pudgy Proliferation. It's happening in front of you... ...

Joining us now, Republican Congressman of South Dakota, Dusty Johnson. Thanks for coming on the program. Uh, Congressman, when the speaker says he is working through, what does that mean.What are your observations about getting this bill to what where I know you want it to be, which is the finish line. I mean, the holdouts are concerned about good policy. They want to make sure that this bill, particularly in areas related to Medicaid, move our country in the right place.I spent two hours at the White House ...

Group 1 - The article promotes a weekly newsletter focused on stocks in the biotech, pharma, and healthcare industries, aimed at both novice and experienced investors [1] - The newsletter provides insights on key trends, catalysts driving valuations, product sales forecasts, and integrated financial statements for major pharmaceutical companies [1] - The author, Edmund Ingham, has over 5 years of experience in covering biotech, healthcare, and pharma, and has prepared detailed reports on more than 1,000 companies [1]